Effect of electrochemotherapy on myogenesis of mouse C2C12 cells in vitro.
Bleomycin
Cisplatin
Electrochemotherapy
Electroporation
Myogenesis
Skeletal muscle
Journal
Bioelectrochemistry (Amsterdam, Netherlands)
ISSN: 1878-562X
Titre abrégé: Bioelectrochemistry
Pays: Netherlands
ID NLM: 100953583
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
07
02
2023
revised:
07
06
2023
accepted:
07
06
2023
medline:
24
7
2023
pubmed:
25
6
2023
entrez:
24
6
2023
Statut:
ppublish
Résumé
Electrochemotherapy (ECT) is a local ablative therapy for the treatment of different skin and subcutaneous tumors and certain tumors in internal organs. Skeletal muscle represents a major tumor- surrounding tissue, exposed to side effects of ECT. At the cellular level, side-effects of ECT on skeletal muscle and underlying mechanisms have not been examined yet. Thus, we aimed to determine the effect of ECT in the mouse muscle cell line C2C12 during in vitro myogenesis. We evaluated the electroporation efficiency and viability of C2C12 myotubes at increasing voltages (200-1300 V/cm) using propidium iodide (PI). Permeabilization of PI into the cells was voltage-dependent accounting up to 97 % efficiency at the highest voltage. High cell viability and myotube integrity were maintained until 4 days after electroporation. ECT with the cytostatic drugs bleomycin and cisplatin decreased the viability of C2C12 myoblasts and myotubes in a dose-dependent manner. However, myoblasts were more sensitive to ECT than myotubes. Increased secretion of IL-6, observed 3 days after ECT, confirming its effects on early myogenesis. Only minor effects of ECT were observed in treated myotubes. These results contribute to the safety profile of ECT in tumor treatment.
Identifiants
pubmed: 37354641
pii: S1567-5394(23)00124-X
doi: 10.1016/j.bioelechem.2023.108487
pii:
doi:
Substances chimiques
Bleomycin
11056-06-7
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
108487Informations de copyright
Copyright © 2023. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.